Results 261 to 270 of about 5,492,450 (303)

Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study

, 1995
COSTA D, THE ITALIAN TUBERCULOSIS DRUG RESISTANCE STUDY GROUP, ANGARANO, Gioacchino, CARBONARA S   +3 more
core  

Proceedings of the Second World Congress on Extensive Reading

, 2015
Extensive Reading Foundation
core  

Some of the next articles are maybe not open access.

Related searches:

Extensively Drug-resistant Tuberculosis

The American Journal of Medicine, 2008
Extensively drug-resistant tuberculosis (XDR-TB) is defined as Mycobacterium tuberculosis infection that is resistant to isoniazid, rifampin, any fluoroquinolone, and any injectable drug (amynoglicosides or polypetides). Although initially described in South Africa, it has emerged as a global threat, and cases have been reported from several countries,
Miguel G, Madariaga, Umesh G, Lalloo, Susan, Swindells   +2 more
  +8 more sources

Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

The Indian Journal of Pediatrics, 2020
India is one of the high burden countries for tuberculosis (TB) including multi-drug resistant TB (MDR-TB) and extensively-drug resistant (XDR) TB. Drug-resistant (DR) TB has threatened the TB care and is a major health problem in many countries; treatment of DR TB has been difficult requiring use of reserve or second-line drugs, cost factors, has ...
Ira, Shah, Vishrutha, Poojari, Himali, Meshram   +2 more
openaire   +2 more sources

Cutaneous Extensively Drug-Resistant Tuberculosis

The American Journal of Tropical Medicine and Hygiene, 2007
A 48-year-old immunocompetent man without known exposure to tuberculosis had a > 10-year history of recurrent skin lesions. Cutaneous tuberculosis without any current or past history of pulmonary tuberculosis was diagnosed. Culture of biopsy specimens showed the organism to be resistant to multiple first-line and second-line agents.
Douglas P, Olson, Cheryl L, Day, Nombulelo P, Magula, Faieza, Sahid, Mahomed-Yunus S, Moosa   +4 more
openaire   +2 more sources

Controlling extensively drug-resistant tuberculosis

The Lancet, 2007
Recent successes in the fight against tuberculosis rely on short-course chemotherapy with our two most powerful drugs isoniazid and rifampicin. Unfortunately not only do hundreds of thousands of people or more still die every year of curable tuberculosis1 but inadequate treatment has also contributed to the origination of strains of tuberculosis ...
Travis C, Porco, Wayne M, Getz
openaire   +2 more sources

Multidrug and extensively drug-resistant tuberculosis

Médecine et Maladies Infectieuses, 2017
The emergence of drug-resistant tuberculosis (TB) compromises global tuberculosis control. The incidence of multidrug-resistant strains (MDR) defined as resistant to the two main antituberculosis drugs, rifampicin and isoniazid, was raised in the 1990s.
Maitre, Thomas, Aubry, A., Jarlier, V., Robert, J., Veziris, Nicolas, Bernard, C., Sougakoff, W., Brossier, F., Cambau, E., Mougari, F., Raskine, L.   +10 more
openaire   +4 more sources

Delamanid for Extensively Drug-Resistant Tuberculosis

New England Journal of Medicine, 2015
Therapeutic options for extensively drug-resistant tuberculosis infection are limited. In this post-hoc analysis, a new drug, delamanid, shows some activity in the treatment of XDR-TB.
Rajesh, Gupta, Lawrence J, Geiter, Charles D, Wells, Mengqui, Gao, Andra, Cirule, Heping, Xiao   +5 more
openaire   +2 more sources